LABUVIRTIDE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C204H306N54O72
Molecular Weight	4666.931
Optical Activity	UNSPECIFIED
Defined Stereocenters	38 / 38
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC5=CC=C(O)C=C5)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN6C(=O)C=CC6=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC7=CNC=N7)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O

InChI

InChIKey=DJIGFNCGXOAXOW-WTPNCWHFSA-N

InChI=1S/C204H306N54O72/c1-17-100(12)166(200(325)240-128(51-66-163(289)290)180(305)232-127(50-65-162(287)288)185(310)253-143(93-259)199(324)238-120(43-56-147(209)266)181(306)248-139(86-149(211)268)191(316)234-119(42-55-146(208)265)176(301)227-117(40-53-144(206)263)174(299)229-121(44-59-156(275)276)177(302)225-114(33-24-26-69-205)172(297)247-138(85-148(210)267)192(317)237-123(46-61-158(279)280)178(303)228-118(41-54-145(207)264)175(300)230-124(47-62-159(281)282)182(307)242-131(78-97(6)7)187(312)241-130(170(214)295)77-96(4)5)255-197(322)133(80-99(10)11)244-183(308)126(49-64-161(285)286)236-190(315)137(84-108-92-217-95-223-108)251-201(326)168(102(14)19-3)256-196(321)132(79-98(8)9)243-173(298)115(34-25-27-70-218-153(272)94-330-76-75-329-74-72-219-152(271)68-73-258-154(273)57-58-155(258)274)239-203(328)169(103(15)260)257-198(323)134(81-105-36-38-109(262)39-37-105)245-193(318)140(87-150(212)269)249-194(319)141(88-151(213)270)252-202(327)167(101(13)18-2)254-186(311)129(52-67-164(291)292)233-171(296)116(35-28-71-220-204(215)216)226-195(320)142(89-165(293)294)250-189(314)136(83-107-91-222-113-32-23-21-30-111(107)113)246-184(309)125(48-63-160(283)284)231-179(304)122(45-60-157(277)278)235-188(313)135(224-104(16)261)82-106-90-221-112-31-22-20-29-110(106)112/h20-23,29-32,36-39,57-58,90-92,95-103,114-143,166-169,221-222,259-260,262H,17-19,24-28,33-35,40-56,59-89,93-94,205H2,1-16H3,(H2,206,263)(H2,207,264)(H2,208,265)(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,295)(H,217,223)(H,218,272)(H,219,271)(H,224,261)(H,225,302)(H,226,320)(H,227,301)(H,228,303)(H,229,299)(H,230,300)(H,231,304)(H,232,305)(H,233,296)(H,234,316)(H,235,313)(H,236,315)(H,237,317)(H,238,324)(H,239,328)(H,240,325)(H,241,312)(H,242,307)(H,243,298)(H,244,308)(H,245,318)(H,246,309)(H,247,297)(H,248,306)(H,249,319)(H,250,314)(H,251,326)(H,252,327)(H,253,310)(H,254,311)(H,255,322)(H,256,321)(H,257,323)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H4,215,216,220)/t100-,101-,102-,103+,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,166-,167-,168-,169-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C204H306N54O72
Molecular Weight	4666.931
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	38 / 38
E/Z Centers	30
Optical Activity	UNSPECIFIED

Approval Year

PubMed

Title	Date	PubMed
Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.	2012	22403678

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:04:42 UTC 2023` Edited by `admin` on `Sat Dec 16 12:04:42 UTC 2023`
Record UNII	MG9PC54E43
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LABUVIRTIDE

Official Name

English

ALBUVIRTIDE

Common Name

English

FB-006M

Code

English

Albuvirtide [WHO-DD]

Common Name

English

L-LEUCINAMIDE, N-ACETYL-L-TRYPTOPHYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-TRYPTOPHYL-L-.ALPHA.-ASPARTYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-ASPARAGINYL-L-ASPARAGINYL-L-TYROSYL-L-THREONYL-N6-(2-(2-(2-((3-(2,5-DIHYDRO-2,5-DIOXO-1H-PYRROL-1-YL)-1-

Systematic Name

English

labuvirtide [INN]

Common Name

English

Code System Code Type Description

INN

11556

Created by admin on Sat Dec 16 12:04:43 UTC 2023 , Edited by admin on Sat Dec 16 12:04:43 UTC 2023

PRIMARY

INN

CAS

1417179-66-8

Created by admin on Sat Dec 16 12:04:42 UTC 2023 , Edited by admin on Sat Dec 16 12:04:42 UTC 2023

NON-SPECIFIC SUBSTITUTION

DRUG BANK

DB15166

Created by admin on Sat Dec 16 12:04:42 UTC 2023 , Edited by admin on Sat Dec 16 12:04:42 UTC 2023

PRIMARY

FDA UNII

MG9PC54E43

Created by admin on Sat Dec 16 12:04:42 UTC 2023 , Edited by admin on Sat Dec 16 12:04:42 UTC 2023

PRIMARY

PUBCHEM

134694278

Created by admin on Sat Dec 16 12:04:43 UTC 2023 , Edited by admin on Sat Dec 16 12:04:43 UTC 2023

PRIMARY

CAS

2395796-76-4

Created by admin on Sat Dec 16 12:04:42 UTC 2023 , Edited by admin on Sat Dec 16 12:04:42 UTC 2023

PRIMARY

NCI_THESAURUS

C179096

Created by admin on Sat Dec 16 12:04:43 UTC 2023 , Edited by admin on Sat Dec 16 12:04:43 UTC 2023

PRIMARY

Related Record Type Details


					859A956UY8

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					MG9PC54E43

LABUVIRTIDE

ACTIVE MOIETY

Comments:

Class: Antiviral, Maleimide, Peptide; Mechanism of Action: HIV envelope protein gp41 inhibitor, HIV fusion inhibitor; Highest Development Phase: Phase III for HIV infections; Most Recent Events: 06 Jun 2016 Interim efficacy and safety data from the phase III TALENT trial in HIV infections released by Frontiers Biotechnologies, 06 Jun 2016 Frontier Biotechnologies announces intention to submit NDA to China Food and Drug Administration in 2016, 21 Mar 2016 Albuvirtide is still in phase III trials for HIV infections (Combination therapy Treatment-experienced patients) in China (IV)

Amount: